MarketCapExport financials
Orchard Therapeutics plc (ORTX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Orchard Therapeutics plc Balance Sheet 2022-2011 | ORTX
Brief balance sheet overview of Orchard Therapeutics plc
The balance sheet is assessed across five available annual reports spanning 2018 to 2022.
The asset base decreased -40.2%, from $366 million to $218.9 million. Resources became smaller over the five periods.
Liabilities grew faster than assets: +120.5% versus -40.2%. A substantial part of expansion was externally funded.
Shareholders' equity accounts for 44.9% of assets, previously 85.1%. Dependence on liabilities is moderate.
Cash exceeds interest-bearing debt, producing net debt of -$39 million. The balance sheet therefore carries a net cash position.
Cash equals 31.3% of the balance sheet, compared with 91.8% five periods ago. This is the readily available cushion.
The balance sheet includes a negative accumulated result of -$900.9 million. It should be assessed alongside historical profits and capital distributions.
Overall picture
Orchard Therapeutics plc's financial structure is not clear-cut. Asset scale alone does not resolve questions about how those assets are funded.
Annual Balance Sheet Orchard Therapeutics plc
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-39 M | -16.5 M | -26 M | 11.5 M | -336 M | -89.9 M | -3.5 M | - | - | - | - | - |
Long Term Debt |
23 M | 32.1 M | 20.2 M | 24.7 M | - | - | - | - | - | - | - | - |
Long Term Debt Current |
6.42 M | 7.34 M | 8.93 M | 5.89 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | 50.9 M | 44.2 M | 6.8 M | 134 K | 17 M | - | - | - | - | - |
Total Current Liabilities |
60.6 M | 42.8 M | 51.6 M | 55.9 M | 47.9 M | 10.8 M | - | - | - | - | - | - |
Total Liabilities |
121 M | 112 M | 103 M | 100 M | 54.7 M | 10.9 M | 20.8 M | - | - | - | - | - |
Deferred Revenue |
959 K | 346 K | - | - | - | 2.27 M | - | - | - | - | - | - |
Retained Earnings |
-901 M | -750 M | -606 M | -454 M | -290 M | -59.7 M | -19.7 M | - | - | - | - | - |
Total Assets |
219 M | 322 M | 281 M | 399 M | 366 M | 97.3 M | 4.28 M | - | - | - | - | - |
Cash and Cash Equivalents |
68.4 M | 55.9 M | 55.1 M | 19.1 M | 336 M | 89.9 M | - | - | - | - | - | - |
Book Value |
98.3 M | 210 M | 178 M | 299 M | 311 M | 86.4 M | -16.5 M | - | - | - | - | - |
Total Shareholders Equity |
98.3 M | 210 M | 178 M | 299 M | 311 M | 86.4 M | -16.5 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Orchard Therapeutics plc
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
16.2 M | 18.4 M | 20.7 M | 23 M | 25.3 M | 27.5 M | 29.8 M | 32.1 M | 32.8 M | 32.7 M | 18.2 M | 20.2 M | 22.2 M | 24.2 M | 24.8 M | 24.7 M | 24.6 M | 24.5 M | 24.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
122 M | 123 M | 115 M | 121 M | 110 M | 113 M | 116 M | 112 M | 114 M | 100 M | 93.5 M | 103 M | 91.2 M | 87.6 M | 90.3 M | 100 M | 75 M | 87 M | 41.8 M | 54.7 M | - | - | - | 10.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
742 K | 752 K | 634 K | 959 K | 1.38 M | 1.15 M | 889 K | 346 K | 1.39 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-966 M | -931 M | -918 M | -901 M | -893 M | -845 M | -795 M | -750 M | -714 M | -677 M | -641 M | -606 M | -572 M | -552 M | -504 M | -454 M | -408 M | -372 M | -321 M | -290 M | - | - | - | -59.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
202 M | 232 M | 217 M | 219 M | 234 M | 259 M | 292 M | 322 M | 356 M | 365 M | 389 M | 281 M | 298 M | 315 M | 355 M | 399 M | 415 M | 458 M | 329 M | 366 M | - | - | - | 97.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
23.5 M | 38.3 M | 61.5 M | 68.4 M | 80.8 M | 53.5 M | 60.8 M | 55.9 M | 74.3 M | 99.9 M | 78.9 M | 55.1 M | 41.2 M | 41.2 M | 27.1 M | 19.1 M | 35.5 M | 133 M | 295 M | 336 M | - | - | - | 89.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
80.3 M | 109 M | 102 M | 98.3 M | 124 M | 146 M | 176 M | 210 M | 241 M | 264 M | 296 M | 178 M | 207 M | 227 M | 265 M | 299 M | 340 M | 371 M | 287 M | 311 M | - | - | - | 86.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
80.3 M | 109 M | 102 M | 98.3 M | 124 M | 146 M | 176 M | 210 M | 241 M | 264 M | 296 M | 178 M | 207 M | 227 M | 265 M | 299 M | 340 M | 371 M | 287 M | 311 M | 131 M | 14.7 M | 77.9 M | 86.4 M | - | - | - | -16.5 M | - | - | - | -572 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Orchard Therapeutics plc, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Britain
USA
Australia
Israel
Germany
China
Canada
Russia
Niderland
